Logo image of KZR

KEZAR LIFE SCIENCES INC (KZR) Stock Fundamental Analysis

USA - NASDAQ:KZR - US49372L2097 - Common Stock

3.79 USD
-0.1 (-2.57%)
Last: 9/24/2025, 1:26:23 PM
Fundamental Rating

2

Overall KZR gets a fundamental rating of 2 out of 10. We evaluated KZR against 538 industry peers in the Biotechnology industry. The financial health of KZR is average, but there are quite some concerns on its profitability. KZR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KZR has reported negative net income.
KZR had a negative operating cash flow in the past year.
In the past 5 years KZR always reported negative net income.
KZR had a negative operating cash flow in each of the past 5 years.
KZR Yearly Net Income VS EBIT VS OCF VS FCFKZR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

KZR's Return On Assets of -57.88% is in line compared to the rest of the industry. KZR outperforms 44.42% of its industry peers.
KZR's Return On Equity of -71.62% is in line compared to the rest of the industry. KZR outperforms 55.76% of its industry peers.
Industry RankSector Rank
ROA -57.88%
ROE -71.62%
ROIC N/A
ROA(3y)-42.23%
ROA(5y)-35.85%
ROE(3y)-50.4%
ROE(5y)-41.71%
ROIC(3y)N/A
ROIC(5y)N/A
KZR Yearly ROA, ROE, ROICKZR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

KZR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZR Yearly Profit, Operating, Gross MarginsKZR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KZR has been increased compared to 1 year ago.
The number of shares outstanding for KZR has been reduced compared to 5 years ago.
The debt/assets ratio for KZR is higher compared to a year ago.
KZR Yearly Shares OutstandingKZR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KZR Yearly Total Debt VS Total AssetsKZR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -4.65, we must say that KZR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.65, KZR is in line with its industry, outperforming 40.89% of the companies in the same industry.
KZR has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
KZR has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: KZR outperforms 40.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -4.65
ROIC/WACCN/A
WACC11.18%
KZR Yearly LT Debt VS Equity VS FCFKZR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 6.76 indicates that KZR has no problem at all paying its short term obligations.
KZR has a Current ratio of 6.76. This is in the better half of the industry: KZR outperforms 68.03% of its industry peers.
A Quick Ratio of 6.76 indicates that KZR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.76, KZR is in the better half of the industry, outperforming 68.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.76
Quick Ratio 6.76
KZR Yearly Current Assets VS Current LiabilitesKZR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for KZR have decreased strongly by -50.00% in the last year.
Looking at the last year, KZR shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.65% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.85%
EPS Next 2Y19.32%
EPS Next 3Y13.39%
EPS Next 5Y11.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KZR Yearly Revenue VS EstimatesKZR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2029 2030 2031 2032 50M 100M 150M 200M 250M
KZR Yearly EPS VS EstimatesKZR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KZR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZR Price Earnings VS Forward Price EarningsKZR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZR Per share dataKZR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

KZR's earnings are expected to grow with 13.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.32%
EPS Next 3Y13.39%

More info and screens

0

5. Dividend

5.1 Amount

KZR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEZAR LIFE SCIENCES INC

NASDAQ:KZR (9/24/2025, 1:26:23 PM)

3.79

-0.1 (-2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners56.29%
Inst Owner Change3.85%
Ins Owners2.16%
Ins Owner Change-0.01%
Market Cap27.74M
Analysts78
Price Target12.75 (236.41%)
Short Float %12.57%
Short Ratio15.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.76%
Min EPS beat(2)4.91%
Max EPS beat(2)12.62%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.91%
Max EPS beat(4)16.56%
EPS beat(8)5
Avg EPS beat(8)3.47%
EPS beat(12)9
Avg EPS beat(12)5.46%
EPS beat(16)11
Avg EPS beat(16)4.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.24
EV/EBITDA N/A
EPS(TTM)-9.69
EYN/A
EPS(NY)-6.48
Fwd EYN/A
FCF(TTM)-10.14
FCFYN/A
OCF(TTM)-10.14
OCFYN/A
SpS0
BVpS15.97
TBVpS15.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.88%
ROE -71.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.23%
ROA(5y)-35.85%
ROE(3y)-50.4%
ROE(5y)-41.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.76
Quick Ratio 6.76
Altman-Z -4.65
F-Score2
WACC11.18%
ROIC/WACCN/A
Cap/Depr(3y)109.16%
Cap/Depr(5y)72.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
EPS Next Y23.85%
EPS Next 2Y19.32%
EPS Next 3Y13.39%
EPS Next 5Y11.65%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.1%
OCF growth 3YN/A
OCF growth 5YN/A